Top

Published in:

01-12-2010 | Clinical Trials Report

Breast Cancer Prevention: An Update of the STAR Trial

Author: Therese B. Bevers, MD

Published in: Current Treatment Options in Oncology | Issue 3-4/2010

Excerpt

Vogel VG, Costantino JP, Wickerham DL, et al.: Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res 2010, 3(6):696–706. …

Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371–1388.CrossRefPubMed

Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727–2741.CrossRefPubMed

Vogel VG, Costantino JP, Wickerham DL, et al.: Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res 2010, 3(6):696–706.CrossRef

Fisher B, Costantino J, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005, 97:1652–1662.CrossRefPubMed

Powles TJ, Ashley S, Tidy A, et al.: Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283–290.CrossRefPubMed

Cuzick J, Forbes JF, Sestak I, et al.: Long-term results of tamoxifen prophylaxis for breast cancer—96 month follow-up of the randomized IBIS-1 trial. J Natl Cancer Inst 2007, 99:272–282.CrossRefPubMed

Title: Breast Cancer Prevention: An Update of the STAR Trial
Author: Therese B. Bevers, MD
Publication date: 01-12-2010
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 3-4/2010
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-010-0124-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3-4/2010

Phytochemicals in the Oncology Setting

Mechanisms of Action for Acupuncture in the Oncology Setting

HER2 Blockade: Is Combination Therapy Better Than Monotherapy?

Erratum to: Exercise Therapy in the Management of Solid Tumors

Duration of Chemotherapy for Early Stage Breast Cancer: Have We Reached the Limit? What is the Survival Impact of Amenorrhea?

Mind–Body Therapies in Integrative Oncology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer